← Back to Search

CAR T-cell Therapy

CTX131 for Resistant or Recurrent Cancer

Phase 1 & 2

Recruiting

Research Sponsored by CRISPR Therapeutics AG

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18 years

Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, endometrial carcinoma, and malignant pleural mesothelioma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from ctx131 infusion up to 60 months post-infusion

Awards & highlights

Study Summary

This trial tests a new therapy for cancer recurrence or resistance to current treatments.

Who is the study for?

Adults over 18 with certain advanced cancers (like kidney, cervical, pancreatic cancer, and mesothelioma) that have come back or didn't respond to treatment. They must be in good physical condition and agree to use birth control for a year after getting the study drug.Check my eligibility

What is being tested?

The trial is testing CTX131's safety and effectiveness on patients with specific solid tumors that are either untreatable or have returned after treatment. It's an early-phase study where everyone gets the same experimental therapy.See study design

What are the potential side effects?

While not specified here, similar treatments often cause immune reactions, fatigue, nausea, potential organ inflammation, increased infection risk and may affect blood cell counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My cancer is advanced and cannot be removed by surgery.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from ctx131 infusion up to 60 months post-infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from ctx131 infusion up to 60 months post-infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and from ctx131 infusion up to 60 months post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Phase 1 (Dose Escalation): Incidence of adverse events

Phase 2 (Cohort Expansion): Objective response rate (ORR)

Trial Design

1Treatment groups

Experimental Treatment

Group I: CTX131Experimental Treatment1 Intervention

Administered by IV infusion following lymphodepleting chemotherapy.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor

8 Previous Clinical Trials

642 Total Patients Enrolled

Alissa Keegan, MD, PhDStudy DirectorCRISPR Therapeutics

Media Library

CTX131 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05795595 — Phase 1 & 2

Pancreatic Adenocarcinoma Research Study Groups: CTX131

Pancreatic Adenocarcinoma Clinical Trial 2023: CTX131 Highlights & Side Effects. Trial Name: NCT05795595 — Phase 1 & 2

CTX131 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05795595 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research open to participation by individuals currently?

"According to clinicaltrials.gov, this medical trial is currently enrolling patients. It was posted on March 1st 2023 and the listing has been freshly updated as of March 21st 2023."

Answered by AI

What is the total capacity for enrollees in this clinical trial?

"Indeed, the information posted on clinicaltrials.gov supports that this medical trial is currently open for recruitment and was initially published on March 1st 2023. The study requires 250 participants from a single site to be enrolled."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

2023. "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05795595.

All > Mesothelioma